Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination
Open Access
- 17 May 2022
- Vol. 10 (5), 796
- https://doi.org/10.3390/vaccines10050796
Abstract
Waning immunity against SARS-CoV-2 and the emergence of variants, especially of the most distant variant, Omicron, affect titers of neutralizing antibodies in the sera of vaccinated individuals. Thus, two vaccinations with the mRNA vaccine BNT162b fail to induce neutralizing antibodies against the Omicron variant. A first booster vaccination increases Omicron-RBD-binding IgG and IgA and neutralizing capacity. In comparison, the Wuhan isolate titers of the Omicron variant binding antibodies are 8.5 lower. After a third vaccination, induction of Omicron-RBD- and Wuhan-RBD-binding antibodies follows the same kinetic. Five to six months after the third vaccination, there are still Omicron-RBD-binding antibodies detectable, but 35.9 percent of the analyzed sera fail to neutralize the Omicron variant, while all sera efficiently neutralize the Delta isolate. In the case of the Wuhan-RBD, a significantly larger number of stable antigen–antibody complexes is formed than in Omicron-RBD. A fourth vaccination with mRNA-1273 temporarily restores levels of Omicron-, Delta- and Wuhan-specific antibodies. Comparing different booster strategies revealed that the breadth of the immune response is not affected by the vaccination regimen. Taken together, these data indicate that booster vaccinations (third and fourth dose) increase the breadth of the immune response, but there is a qualitative difference of antibodies with respect to the stability of antigen–antibody complexes and persistence of antibody titers.Funding Information
- Horizon Health Network (871029)
- Federal Ministry of Health (VARIPATH)
This publication has 17 references indexed in Scilit:
- Comirnaty-Elicited and Convalescent Sera Recognize Different Spike EpitopesVaccines, 2021
- Analysis of BNT162b2‐ and CVnCoV‐elicited sera and of convalescent sera toward SARS‐CoV‐2 virusesAllergy, 2021
- Waning Immunity after the BNT162b2 Vaccine in IsraelThe New England Journal of Medicine, 2021
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escapeNature, 2021
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Impact of the Delta variant on vaccine efficacy and response strategiesExpert Review of Vaccines, 2021
- Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studiesInflammopharmacology, 2021
- Cell‐by‐cell approximate Schur complement technique in preconditioning of meshfree discretized piezoelectric equationsNumerical Linear Algebra with Applications, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020